TY - JOUR
T1 - Comprehensive Analysis of the 5xFAD Mouse Model of Alzheimer's Disease Using dMRI, Immunohistochemistry, and Neuronal and Glial Functional Metabolic Mapping
AU - Westi, Emil W
AU - Molhemi, Saba
AU - Hansen, Caroline Termøhlen
AU - Skoven, Christian Stald
AU - Knopper, Rasmus West
AU - Ahmad, Dashne Amein
AU - Rindshøj, Maja B
AU - Ameen, Aishat O
AU - Hansen, Brian
AU - Kohlmeier, Kristi A
AU - Aldana, Blanca I
PY - 2024
Y1 - 2024
N2 - Alzheimer's disease (AD) is characterized by complex interactions between neuropathological markers, metabolic dysregulation, and structural brain changes. In this study, we utilized a multimodal approach, combining immunohistochemistry, functional metabolic mapping, and microstructure sensitive diffusion MRI (dMRI) to progressively investigate these interactions in the 5xFAD mouse model of AD. Our analysis revealed age-dependent and region-specific accumulation of key AD markers, including amyloid-beta (Aβ), GFAP, and IBA1, with significant differences observed between the hippocampal formation and upper and lower regions of the cortex by 6 months of age. Functional metabolic mapping validated localized disruptions in energy metabolism, with glucose hypometabolism in the hippocampus and impaired astrocytic metabolism in the cortex. Notably, increased cortical glutaminolysis suggested a shift in microglial metabolism, reflecting an adaptive response to neuroinflammatory processes. While dMRI showed no significant microstructural differences between 5xFAD and wild-type controls, the study highlights the importance of metabolic alterations as critical events in AD pathology. These findings emphasize the need for targeted therapeutic strategies addressing specific metabolic disturbances and underscore the potential of integrating advanced imaging with metabolic and molecular analyses to advance our understanding of AD progression.
AB - Alzheimer's disease (AD) is characterized by complex interactions between neuropathological markers, metabolic dysregulation, and structural brain changes. In this study, we utilized a multimodal approach, combining immunohistochemistry, functional metabolic mapping, and microstructure sensitive diffusion MRI (dMRI) to progressively investigate these interactions in the 5xFAD mouse model of AD. Our analysis revealed age-dependent and region-specific accumulation of key AD markers, including amyloid-beta (Aβ), GFAP, and IBA1, with significant differences observed between the hippocampal formation and upper and lower regions of the cortex by 6 months of age. Functional metabolic mapping validated localized disruptions in energy metabolism, with glucose hypometabolism in the hippocampus and impaired astrocytic metabolism in the cortex. Notably, increased cortical glutaminolysis suggested a shift in microglial metabolism, reflecting an adaptive response to neuroinflammatory processes. While dMRI showed no significant microstructural differences between 5xFAD and wild-type controls, the study highlights the importance of metabolic alterations as critical events in AD pathology. These findings emphasize the need for targeted therapeutic strategies addressing specific metabolic disturbances and underscore the potential of integrating advanced imaging with metabolic and molecular analyses to advance our understanding of AD progression.
KW - Animals
KW - Alzheimer Disease/metabolism
KW - Mice
KW - Disease Models, Animal
KW - Mice, Transgenic
KW - Immunohistochemistry
KW - Neurons/metabolism
KW - Neuroglia/metabolism
KW - Diffusion Magnetic Resonance Imaging
KW - Amyloid beta-Peptides/metabolism
KW - Hippocampus/metabolism
KW - Male
KW - Brain/metabolism
KW - Astrocytes/metabolism
KW - Female
U2 - 10.3390/biom14101294
DO - 10.3390/biom14101294
M3 - Journal article
C2 - 39456227
SN - 2218-273X
VL - 14
JO - Biomolecules
JF - Biomolecules
IS - 10
M1 - 1294
ER -